Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT02044328 2022-02-08

ICAPE

Phase 2 Completed

79 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02448797 2021-07-20

EVIDENCE

Phase 3 Unknown

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04058704 2019-08-15

SMART

Phase 3 Unknown

296 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02726568 2019-02-19

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

30 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03754530 2018-11-27

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

162 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03749213 2018-11-21

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

36 enrolled

EGF-R Positive Non-Small Cell Lung Cancer

NCT03349203 2018-07-18

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

60 enrolled

EGF-R Positive Non-Small Cell Lung Cancer

NCT03396185 2018-07-18

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02125240 2018-07-16

ICWIP

Phase 3 Unknown

124 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT03346811 2017-11-17

CHALLENGE

120 enrolled

Plasma EGFR Mutation-positive Lung Cancer

NCT02404675 2017-07-28

INCREASE

240 enrolled

NSCLC

NCT01646450 2015-09-09

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01707329 2015-09-09

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01843647 2015-07-15

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01926171 2015-07-15

Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02062515 2015-07-15

Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01720901 2015-05-22

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Phase 4 Suspended

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02027090 2015-05-22

High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease

64 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02278458 2015-05-22

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Phase 1 Unknown

24 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

192 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT02066870 2015-03-13

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Phase 1 Unknown

9 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01465243 2014-02-17

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Phase 4 Completed

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01516983 2014-02-17

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Phase 1/2 Completed

15 enrolled